Leukemia patients test life without daily pills

NCT ID NCT01784068

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested whether patients with a specific type of chronic leukemia could safely stop their daily medication, nilotinib, after it had successfully controlled their disease for a long time. It involved 215 adults whose cancer was in a stable phase and who had achieved a very deep response to the drug. The main goal was to see how many patients could remain in remission for 48 weeks after stopping treatment, with the option to restart the drug if needed.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Cancer Center of Kansas

Wichita, Kansas, 67214-3728, United States
Cancer Centers of the Carolinas

Greenville, South Carolina, 29605, United States
Community Cancer Trials of Utah

Ogden, Utah, 84405, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Florida Cancer Specialists

Fort Myers, Florida, 33901, United States
H Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, 33612, United States
Lakes Research

Miami Lakes, Florida, 33014, United States
Memorial Sloan Kettering

New York, New York, 10017, United States
Novartis Investigative Site

Buenos Aires, C1114AAN, Argentina
Novartis Investigative Site

Graz, 8036, Austria
Novartis Investigative Site

Rankweil, A-6830, Austria
Novartis Investigative Site

Salzburg, 5020, Austria
Novartis Investigative Site

Vienna, 1140, Austria
Novartis Investigative Site

Vienna, A-1130, Austria
Novartis Investigative Site

Sint-Niklaas, Oost Vlaanderen, 9100, Belgium
Novartis Investigative Site

Brussels, 1090, Belgium
Novartis Investigative Site

Brussels, 1200, Belgium
Novartis Investigative Site

Charleroi, 6000, Belgium
Novartis Investigative Site

Ghent, 9000, Belgium
Novartis Investigative Site

Kortrijk, 8500, Belgium
Novartis Investigative Site

Liège, 4000, Belgium
Novartis Investigative Site

Varna, 9000, Bulgaria
Novartis Investigative Site

Bogota, Cundinamarca, 111411, Colombia
Novartis Investigative Site

Montería, 230004, Colombia
Novartis Investigative Site

Aarhus N, 8200, Denmark
Novartis Investigative Site

Bayonne, Bayonne Cedex, 64109, France
Novartis Investigative Site

Saint Priest En Jarez, Pays de la Loire Region, 42270, France
Novartis Investigative Site

Bordeaux, 33076, France
Novartis Investigative Site

Brest, 29609, France
Novartis Investigative Site

Corbeil-Essonnes, 91100, France
Novartis Investigative Site

Dunkirk, 59240, France
Novartis Investigative Site

Grenoble, 38043, France
Novartis Investigative Site

Nantes, 44093, France
Novartis Investigative Site

Rouen, 76038, France
Novartis Investigative Site

Strasbourg, 67000, France
Novartis Investigative Site

Strasbourg, 67085, France
Novartis Investigative Site

Toulouse, 31059, France
Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Novartis Investigative Site

Mannheim, Baden-Wurttemberg, 68305, Germany
Novartis Investigative Site

Frankfurt am Main, Hesse, 60590, Germany
Novartis Investigative Site

Düsseldorf, North Rhine-Westphalia, 40225, Germany
Novartis Investigative Site

Leipzig, Saxony, 04103, Germany
Novartis Investigative Site

Lübeck, Schleswig-Holstein, 23563, Germany
Novartis Investigative Site

Jena, Thuringia, 07740, Germany
Novartis Investigative Site

Aachen, 52074, Germany
Novartis Investigative Site

Bayreuth, 95445, Germany
Novartis Investigative Site

Berlin, 13353, Germany
Novartis Investigative Site

Bonn, 53105, Germany
Novartis Investigative Site

Bottrop, 46236, Germany
Novartis Investigative Site

Dresden, 01307, Germany
Novartis Investigative Site

Düsseldorf, 40479, Germany
Novartis Investigative Site

Goslar, 38642, Germany
Novartis Investigative Site

Hamburg, 20246, Germany
Novartis Investigative Site

Hamburg, 22417, Germany
Novartis Investigative Site

Magdeburg, 39104, Germany
Novartis Investigative Site

Mainz, 55131, Germany
Novartis Investigative Site

Stuttgart, 70376, Germany
Novartis Investigative Site

Ulm, 89081, Germany
Novartis Investigative Site

Athens, 106 76, Greece
Novartis Investigative Site

Athens, 115 27, Greece
Novartis Investigative Site

Budapest, H-1083, Hungary
Novartis Investigative Site

Szeged, 6720, Hungary
Novartis Investigative Site

Dublin, D03 VX82, Ireland
Novartis Investigative Site

Galway, 12074, Ireland
Novartis Investigative Site

Ancona, AN, 60126, Italy
Novartis Investigative Site

Brescia, BS, 25123, Italy
Novartis Investigative Site

Cona, FE, 44100, Italy
Novartis Investigative Site

Florence, FI, 50134, Italy
Novartis Investigative Site

Genova, GE, 16132, Italy
Novartis Investigative Site

Nuoro, NU, 08100, Italy
Novartis Investigative Site

Perugia, PG, 06129, Italy
Novartis Investigative Site

Reggio Calabria, RC, 89100, Italy
Novartis Investigative Site

Roma, RM, 00161, Italy
Novartis Investigative Site

Orbassano, TO, 10043, Italy
Novartis Investigative Site

Terni, TR, 05100, Italy
Novartis Investigative Site

Naples, 80132, Italy
Novartis Investigative Site

Novara, 28100, Italy
Novartis Investigative Site

Kashiwa, Chiba, 277-8567, Japan
Novartis Investigative Site

Sapporo, Hokkaido, 060 8648, Japan
Novartis Investigative Site

Sagamihara, Kanagawa, 252-0375, Japan
Novartis Investigative Site

Ōsaka-sayama, Osaka, 589 8511, Japan
Novartis Investigative Site

Suita, Osaka, 565 0871, Japan
Novartis Investigative Site

Saga, Saga-ken, 849-8501, Japan
Novartis Investigative Site

Kawagoe, Saitama, 350 8550, Japan
Novartis Investigative Site

Shimotsuga Gun, Tochigi, 321-0293, Japan
Novartis Investigative Site

Bunkyo-ku, Tokyo, 113-8519, Japan
Novartis Investigative Site

Shinjuku Ku, Tokyo, 160-0023, Japan
Novartis Investigative Site

Akita, 010-8543, Japan
Novartis Investigative Site

Kumamoto, 860-8556, Japan
Novartis Investigative Site

Groningen, 9713 GZ, Netherlands
Novartis Investigative Site

Gdansk, 80-952, Poland
Novartis Investigative Site

Warsaw, 02 106, Poland
Novartis Investigative Site

Terrassa, Catalonia, 08221, Spain
Novartis Investigative Site

Ourense, Galicia, 32005, Spain
Novartis Investigative Site

Pamplona, Navarre, 31008, Spain
Novartis Investigative Site

Oviedo, Principality of Asturias, 33011, Spain
Novartis Investigative Site

San Cristóbal de La Laguna, Santa Cruz De Tenerife, 38320, Spain
Novartis Investigative Site

Barakaldo, Vizcaya, 48903, Spain
Novartis Investigative Site

Barcelona, 08041, Spain
Novartis Investigative Site

Las Palmas de Gran Canaria, 35010, Spain
Novartis Investigative Site

Madrid, 28006, Spain
Novartis Investigative Site

Madrid, 28034, Spain
Novartis Investigative Site

Madrid, 28040, Spain
Novartis Investigative Site

Madrid, 28041, Spain
Novartis Investigative Site

Madrid, 28046, Spain
Novartis Investigative Site

Tarragona, 43005, Spain
Novartis Investigative Site

Lund, SE-221 85, Sweden
Novartis Investigative Site

Stockholm, SE-171 76, Sweden
Novartis Investigative Site

Uppsala, SE-751 85, Sweden
Novartis Investigative Site

Cardiff, CF14 4XW, United Kingdom
Novartis Investigative Site

Oxford, OX3 7LE, United Kingdom
Oregon Health Sciences University

Portland, Oregon, 97239, United States
Tennessee Oncology PLLC

Chattanooga, Tennessee, 37404, United States

Conditions

Explore the condition pages connected to this study.

CHRONIC MYELOGENOUS LEUKEMIA